Treatment response to ritonavir-boosted tipranavir versus ritonavir-boosted lopinavir in HIV-1 patients with higher lopinavir mutation scores
Week 48 HIV-RNA treatment response to the protease inhibitor tipranavir co-administered with ritonavir was compared with that of lopinavir co-administered with ritonavir in patients whose baseline isolates had varying lopinavir genotypic mutation scores. With increasing lopinavir mutation scores, th...
Gespeichert in:
| Veröffentlicht in: | AIDS (London) 2007-10, Vol.21 (16), p.2245-2248 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2248 |
|---|---|
| container_issue | 16 |
| container_start_page | 2245 |
| container_title | AIDS (London) |
| container_volume | 21 |
| creator | WALMSLEY, Sharon L COTTE, Laurent RUSCONI, Stefano WARD, Douglas J HICKS, Charles B MEIER, Ulrich VALDEZ, Hernan BOUCHER, Charles A. B |
| description | Week 48 HIV-RNA treatment response to the protease inhibitor tipranavir co-administered with ritonavir was compared with that of lopinavir co-administered with ritonavir in patients whose baseline isolates had varying lopinavir genotypic mutation scores. With increasing lopinavir mutation scores, the proportion of patients achieving a week 48 treatment response was increased in the tipranavir/ritonavir compared with the lopinavir/ritonavir arm. Tipranavir/ritonavir therapy improves treatment response rates compared with lopinavir/ritonavir in patients whose viruses have reduced susceptibility to lopinavir/ritonavir. |
| doi_str_mv | 10.1097/QAD.0b013e3282ef6db7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69079519</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>21052061</sourcerecordid><originalsourceid>FETCH-LOGICAL-c412t-186037c3092aa3fe5dff0b59629d72305d932e164fd4bb5313cd6e2004781db53</originalsourceid><addsrcrecordid>eNqF0dGK1TAQBuAgintcfQOR3Ohd15mkaZrLZVfdhQURVm9L2kw9kbapSbriQ_jORs-BFRG8CjN88-fiZ-w5whmC0a8_nF-eQQ8oSYpW0Ni4Xj9gO6y1rJTS-JDtQDSmMlLDCXuS0hcAUNC2j9kJtmDKUO_Yj9tINs-0ZB4prWFJxHPg0eew2Dsfqz6ElMnx7Ndof6_4HcW0pX-YKaz-QPzCr64_VchXm30JT_ybz3u-95_3FP9w85YLCAtPQyj_P2WPRjslenZ8T9nHt29uL66qm_fvri_Ob6qhRpErbBuQepBghLVyJOXGEXplGmGcFhKUM1IQNvXo6r5XEuXgGhIAtW7RlcUpe3XIXWP4ulHK3ezTQNNkFwpb6hoD2ig0_4UCQQlosMD6AIcYUoo0dmv0s43fO4TuV19d6av7u69y9uKYv_UzufujY0EFvDwCmwY7jaWDwad7Z0SNGqX8CUmdosQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>21052061</pqid></control><display><type>article</type><title>Treatment response to ritonavir-boosted tipranavir versus ritonavir-boosted lopinavir in HIV-1 patients with higher lopinavir mutation scores</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>WALMSLEY, Sharon L ; COTTE, Laurent ; RUSCONI, Stefano ; WARD, Douglas J ; HICKS, Charles B ; MEIER, Ulrich ; VALDEZ, Hernan ; BOUCHER, Charles A. B</creator><creatorcontrib>WALMSLEY, Sharon L ; COTTE, Laurent ; RUSCONI, Stefano ; WARD, Douglas J ; HICKS, Charles B ; MEIER, Ulrich ; VALDEZ, Hernan ; BOUCHER, Charles A. B</creatorcontrib><description>Week 48 HIV-RNA treatment response to the protease inhibitor tipranavir co-administered with ritonavir was compared with that of lopinavir co-administered with ritonavir in patients whose baseline isolates had varying lopinavir genotypic mutation scores. With increasing lopinavir mutation scores, the proportion of patients achieving a week 48 treatment response was increased in the tipranavir/ritonavir compared with the lopinavir/ritonavir arm. Tipranavir/ritonavir therapy improves treatment response rates compared with lopinavir/ritonavir in patients whose viruses have reduced susceptibility to lopinavir/ritonavir.</description><identifier>ISSN: 0269-9370</identifier><identifier>EISSN: 1473-5571</identifier><identifier>DOI: 10.1097/QAD.0b013e3282ef6db7</identifier><identifier>PMID: 18090054</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins</publisher><subject>AIDS/HIV ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antiretroviral Therapy, Highly Active ; Antiviral agents ; Biological and medical sciences ; Clinical Trials, Phase III as Topic ; Drug Administration Schedule ; Drug Resistance, Viral ; HIV Infections - drug therapy ; HIV Infections - virology ; HIV Protease ; HIV Protease Inhibitors - therapeutic use ; HIV-1 - genetics ; Human immunodeficiency virus 1 ; Human viral diseases ; Humans ; Immunodeficiencies ; Immunodeficiencies. Immunoglobulinopathies ; Immunopathology ; Infectious diseases ; Lopinavir ; Medical sciences ; Mutation ; Pharmacology. Drug treatments ; Pyridines - therapeutic use ; Pyrimidinones - therapeutic use ; Pyrones - therapeutic use ; Ritonavir - therapeutic use ; RNA, Viral - blood ; Treatment Outcome ; Viral diseases ; Viral diseases of the lymphoid tissue and the blood. Aids ; Viral Load</subject><ispartof>AIDS (London), 2007-10, Vol.21 (16), p.2245-2248</ispartof><rights>2007 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c412t-186037c3092aa3fe5dff0b59629d72305d932e164fd4bb5313cd6e2004781db53</citedby><cites>FETCH-LOGICAL-c412t-186037c3092aa3fe5dff0b59629d72305d932e164fd4bb5313cd6e2004781db53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19241713$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18090054$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>WALMSLEY, Sharon L</creatorcontrib><creatorcontrib>COTTE, Laurent</creatorcontrib><creatorcontrib>RUSCONI, Stefano</creatorcontrib><creatorcontrib>WARD, Douglas J</creatorcontrib><creatorcontrib>HICKS, Charles B</creatorcontrib><creatorcontrib>MEIER, Ulrich</creatorcontrib><creatorcontrib>VALDEZ, Hernan</creatorcontrib><creatorcontrib>BOUCHER, Charles A. B</creatorcontrib><title>Treatment response to ritonavir-boosted tipranavir versus ritonavir-boosted lopinavir in HIV-1 patients with higher lopinavir mutation scores</title><title>AIDS (London)</title><addtitle>AIDS</addtitle><description>Week 48 HIV-RNA treatment response to the protease inhibitor tipranavir co-administered with ritonavir was compared with that of lopinavir co-administered with ritonavir in patients whose baseline isolates had varying lopinavir genotypic mutation scores. With increasing lopinavir mutation scores, the proportion of patients achieving a week 48 treatment response was increased in the tipranavir/ritonavir compared with the lopinavir/ritonavir arm. Tipranavir/ritonavir therapy improves treatment response rates compared with lopinavir/ritonavir in patients whose viruses have reduced susceptibility to lopinavir/ritonavir.</description><subject>AIDS/HIV</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antiretroviral Therapy, Highly Active</subject><subject>Antiviral agents</subject><subject>Biological and medical sciences</subject><subject>Clinical Trials, Phase III as Topic</subject><subject>Drug Administration Schedule</subject><subject>Drug Resistance, Viral</subject><subject>HIV Infections - drug therapy</subject><subject>HIV Infections - virology</subject><subject>HIV Protease</subject><subject>HIV Protease Inhibitors - therapeutic use</subject><subject>HIV-1 - genetics</subject><subject>Human immunodeficiency virus 1</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Immunodeficiencies</subject><subject>Immunodeficiencies. Immunoglobulinopathies</subject><subject>Immunopathology</subject><subject>Infectious diseases</subject><subject>Lopinavir</subject><subject>Medical sciences</subject><subject>Mutation</subject><subject>Pharmacology. Drug treatments</subject><subject>Pyridines - therapeutic use</subject><subject>Pyrimidinones - therapeutic use</subject><subject>Pyrones - therapeutic use</subject><subject>Ritonavir - therapeutic use</subject><subject>RNA, Viral - blood</subject><subject>Treatment Outcome</subject><subject>Viral diseases</subject><subject>Viral diseases of the lymphoid tissue and the blood. Aids</subject><subject>Viral Load</subject><issn>0269-9370</issn><issn>1473-5571</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqF0dGK1TAQBuAgintcfQOR3Ohd15mkaZrLZVfdhQURVm9L2kw9kbapSbriQ_jORs-BFRG8CjN88-fiZ-w5whmC0a8_nF-eQQ8oSYpW0Ni4Xj9gO6y1rJTS-JDtQDSmMlLDCXuS0hcAUNC2j9kJtmDKUO_Yj9tINs-0ZB4prWFJxHPg0eew2Dsfqz6ElMnx7Ndof6_4HcW0pX-YKaz-QPzCr64_VchXm30JT_ybz3u-95_3FP9w85YLCAtPQyj_P2WPRjslenZ8T9nHt29uL66qm_fvri_Ob6qhRpErbBuQepBghLVyJOXGEXplGmGcFhKUM1IQNvXo6r5XEuXgGhIAtW7RlcUpe3XIXWP4ulHK3ezTQNNkFwpb6hoD2ig0_4UCQQlosMD6AIcYUoo0dmv0s43fO4TuV19d6av7u69y9uKYv_UzufujY0EFvDwCmwY7jaWDwad7Z0SNGqX8CUmdosQ</recordid><startdate>20071018</startdate><enddate>20071018</enddate><creator>WALMSLEY, Sharon L</creator><creator>COTTE, Laurent</creator><creator>RUSCONI, Stefano</creator><creator>WARD, Douglas J</creator><creator>HICKS, Charles B</creator><creator>MEIER, Ulrich</creator><creator>VALDEZ, Hernan</creator><creator>BOUCHER, Charles A. B</creator><general>Lippincott Williams & Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20071018</creationdate><title>Treatment response to ritonavir-boosted tipranavir versus ritonavir-boosted lopinavir in HIV-1 patients with higher lopinavir mutation scores</title><author>WALMSLEY, Sharon L ; COTTE, Laurent ; RUSCONI, Stefano ; WARD, Douglas J ; HICKS, Charles B ; MEIER, Ulrich ; VALDEZ, Hernan ; BOUCHER, Charles A. B</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c412t-186037c3092aa3fe5dff0b59629d72305d932e164fd4bb5313cd6e2004781db53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>AIDS/HIV</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antiretroviral Therapy, Highly Active</topic><topic>Antiviral agents</topic><topic>Biological and medical sciences</topic><topic>Clinical Trials, Phase III as Topic</topic><topic>Drug Administration Schedule</topic><topic>Drug Resistance, Viral</topic><topic>HIV Infections - drug therapy</topic><topic>HIV Infections - virology</topic><topic>HIV Protease</topic><topic>HIV Protease Inhibitors - therapeutic use</topic><topic>HIV-1 - genetics</topic><topic>Human immunodeficiency virus 1</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Immunodeficiencies</topic><topic>Immunodeficiencies. Immunoglobulinopathies</topic><topic>Immunopathology</topic><topic>Infectious diseases</topic><topic>Lopinavir</topic><topic>Medical sciences</topic><topic>Mutation</topic><topic>Pharmacology. Drug treatments</topic><topic>Pyridines - therapeutic use</topic><topic>Pyrimidinones - therapeutic use</topic><topic>Pyrones - therapeutic use</topic><topic>Ritonavir - therapeutic use</topic><topic>RNA, Viral - blood</topic><topic>Treatment Outcome</topic><topic>Viral diseases</topic><topic>Viral diseases of the lymphoid tissue and the blood. Aids</topic><topic>Viral Load</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>WALMSLEY, Sharon L</creatorcontrib><creatorcontrib>COTTE, Laurent</creatorcontrib><creatorcontrib>RUSCONI, Stefano</creatorcontrib><creatorcontrib>WARD, Douglas J</creatorcontrib><creatorcontrib>HICKS, Charles B</creatorcontrib><creatorcontrib>MEIER, Ulrich</creatorcontrib><creatorcontrib>VALDEZ, Hernan</creatorcontrib><creatorcontrib>BOUCHER, Charles A. B</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>AIDS (London)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>WALMSLEY, Sharon L</au><au>COTTE, Laurent</au><au>RUSCONI, Stefano</au><au>WARD, Douglas J</au><au>HICKS, Charles B</au><au>MEIER, Ulrich</au><au>VALDEZ, Hernan</au><au>BOUCHER, Charles A. B</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment response to ritonavir-boosted tipranavir versus ritonavir-boosted lopinavir in HIV-1 patients with higher lopinavir mutation scores</atitle><jtitle>AIDS (London)</jtitle><addtitle>AIDS</addtitle><date>2007-10-18</date><risdate>2007</risdate><volume>21</volume><issue>16</issue><spage>2245</spage><epage>2248</epage><pages>2245-2248</pages><issn>0269-9370</issn><eissn>1473-5571</eissn><abstract>Week 48 HIV-RNA treatment response to the protease inhibitor tipranavir co-administered with ritonavir was compared with that of lopinavir co-administered with ritonavir in patients whose baseline isolates had varying lopinavir genotypic mutation scores. With increasing lopinavir mutation scores, the proportion of patients achieving a week 48 treatment response was increased in the tipranavir/ritonavir compared with the lopinavir/ritonavir arm. Tipranavir/ritonavir therapy improves treatment response rates compared with lopinavir/ritonavir in patients whose viruses have reduced susceptibility to lopinavir/ritonavir.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins</pub><pmid>18090054</pmid><doi>10.1097/QAD.0b013e3282ef6db7</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0269-9370 |
| ispartof | AIDS (London), 2007-10, Vol.21 (16), p.2245-2248 |
| issn | 0269-9370 1473-5571 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69079519 |
| source | MEDLINE; Journals@Ovid Complete; EZB-FREE-00999 freely available EZB journals |
| subjects | AIDS/HIV Antibiotics. Antiinfectious agents. Antiparasitic agents Antiretroviral Therapy, Highly Active Antiviral agents Biological and medical sciences Clinical Trials, Phase III as Topic Drug Administration Schedule Drug Resistance, Viral HIV Infections - drug therapy HIV Infections - virology HIV Protease HIV Protease Inhibitors - therapeutic use HIV-1 - genetics Human immunodeficiency virus 1 Human viral diseases Humans Immunodeficiencies Immunodeficiencies. Immunoglobulinopathies Immunopathology Infectious diseases Lopinavir Medical sciences Mutation Pharmacology. Drug treatments Pyridines - therapeutic use Pyrimidinones - therapeutic use Pyrones - therapeutic use Ritonavir - therapeutic use RNA, Viral - blood Treatment Outcome Viral diseases Viral diseases of the lymphoid tissue and the blood. Aids Viral Load |
| title | Treatment response to ritonavir-boosted tipranavir versus ritonavir-boosted lopinavir in HIV-1 patients with higher lopinavir mutation scores |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T01%3A08%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20response%20to%20ritonavir-boosted%20tipranavir%20versus%20ritonavir-boosted%20lopinavir%20in%20HIV-1%20patients%20with%20higher%20lopinavir%20mutation%20scores&rft.jtitle=AIDS%20(London)&rft.au=WALMSLEY,%20Sharon%20L&rft.date=2007-10-18&rft.volume=21&rft.issue=16&rft.spage=2245&rft.epage=2248&rft.pages=2245-2248&rft.issn=0269-9370&rft.eissn=1473-5571&rft_id=info:doi/10.1097/QAD.0b013e3282ef6db7&rft_dat=%3Cproquest_cross%3E21052061%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=21052061&rft_id=info:pmid/18090054&rfr_iscdi=true |